Vosilasarm is under clinical development by Ellipses Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vosilasarm’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vosilasarm overview
Vosilasarm (EP-0062) is under development for the treatment of relapsed locally advanced or metastatic AR positive / HER-2 negative / ER positive breast cancer. It is administered through oral route. It acts by targeting androgen receptor (AR).
Ellipses Pharma overview
Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access the best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, and biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.
For a complete picture of Vosilasarm’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
